(vianews) - lna sante (lna.pa) is among this list of stock assets with the highest dividend rate and return on equity on the healthcare sector.
| financial asset | price | forward dividend yield | return on equity |
|---|---|---|---|
| lna sante (lna.pa) | €20.45 | 2.54% | 9.08% |
| tubize-fin (tub.br) | €92.40 | 1.06% | 4.97% |
| vetoquinol (veto.pa) | €99.50 | 1.02% | 12.13% |
several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. lna sante (lna.pa)
2.54% forward dividend yield and 9.08% return on equity
lna santé sa engages in the management and operation of health establishments. the company operates retirement homes, medical and rehabilitation care, home hospital, surgery, mental health clinic, and health center. lna santé sa was founded in 1990 and is based in vertou, france.
earnings per share
as for profitability, lna sante has a trailing twelve months eps of €2.28.
pe ratio
lna sante has a trailing twelve months price to earnings ratio of 8.97. meaning, the purchaser of the share is investing €8.97 for every euro of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 9.08%.
stock price classification
according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, lna sante's stock is considered to be overbought (>=80).
more news about lna sante.
2. tubize-fin (tub.br)
1.06% forward dividend yield and 4.97% return on equity
financière de tubize sa operates as a mono holding company whose sole investment is a stake in ucb which is a biopharma company in belgium. the company is based in brussels, belgium.
earnings per share
as for profitability, tubize-fin has a trailing twelve months eps of €1.98.
pe ratio
tubize-fin has a trailing twelve months price to earnings ratio of 46.67. meaning, the purchaser of the share is investing €46.67 for every euro of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.97%.
volatility
tubize-fin's last week, last month's, and last quarter's current intraday variation average was 0.89%, 0.49%, and 1.42%.
tubize-fin's highest amplitude of average volatility was 1.00% (last week), 1.73% (last month), and 1.42% (last quarter).
dividend yield
as maintained by morningstar, inc., the next dividend payment is on apr 30, 2024, the estimated forward annual dividend rate is 0.97 and the estimated forward annual dividend yield is 1.06%.
moving average
tubize-fin's worth is way above its 50-day moving average of €80.20 and way higher than its 200-day moving average of €72.18.more news about tubize-fin.
3. vetoquinol (veto.pa)
1.02% forward dividend yield and 12.13% return on equity
vetoquinol sa, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in europe, the americas, and the asia pacific region. it provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. the company was founded in 1933 and is headquartered in lure, france. vetoquinol sa is a subsidiary of soparfin sca.
earnings per share
as for profitability, vetoquinol has a trailing twelve months eps of €4.97.
pe ratio
vetoquinol has a trailing twelve months price to earnings ratio of 20.02. meaning, the purchaser of the share is investing €20.02 for every euro of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.13%.
stock price classification
according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, vetoquinol's stock is considered to be overbought (>=80).
volume
today's last reported volume for vetoquinol is 4463 which is 47.48% above its average volume of 3026.
volatility
vetoquinol's last week, last month's, and last quarter's current intraday variation average was a negative 1.06%, a negative 0.28%, and a positive 1.39%.
vetoquinol's highest amplitude of average volatility was 1.06% (last week), 1.38% (last month), and 1.39% (last quarter).
moving average
vetoquinol's value is way higher than its 50-day moving average of €83.09 and way higher than its 200-day moving average of €86.42.more news about vetoquinol.